Subcutaneous Abaloparatide in Men with Osteoporosis
Vol: 303| Issue: 2| Number:5| ISSN#: 2564-2537
OE Level Evidence:1
Journal Level of Evidence:1
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical TrialJ Bone Miner Res. 2022 Dec;37(12): 2435-2442.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Two hundred and twenty-eight men with osteoporosis were randomized to receive 12 months of daily subcutaneous abaloparatide (n=149) or placebo (n=79). The primary outcome of interest was the change from baseline in lumbar spine bone mineral density (BMD). Secondary outcomes of interest include BMD of the femoral neck and hip and the incidence of new clinical fractures; safety outcomes were also as...
Join the Conversation
Please Login or Join to leave comments.